At what levels of total low- or high-density lipoprotein cholesterol should diet/drug therapy be initiated? United States guidelines.
At what levels of total low- or high-density lipoprotein cholesterol should diet/drug therapy be initiated? United States guidelines.
复制标题
当低密度脂蛋白胆固醇或高密度脂蛋白胆固醇总量达到什么水平时,应开始饮食/药物治疗?
DOI:
10.1016/0002-9149(90)91247-4
复制
发表时间:
1990
期刊:
影响因子:
--
通讯作者:
J. Larosa
中科院分区:
文献类型:
--
作者:
J. Larosa
Guidelines for the detection, evaluation and treatment of hypercholesterolemia in adults have been established in the United States. These guidelines recommend that total cholesterol levels be used for screening purposes. Total cholesterol levels >240 mg/dl are considered “high,” those from 200 to 239 mg/dl “borderline,” and those <200 mg/dl “normal,” regardless of the person's age or gender. All persons in the high category, as well as those in the borderline category who have other risk factors or established vascular disease, require measurements of low-density lipoprotein (LDL) cholesterol levels. LDL cholesterol levels are used to guide the selection of treatment. Patients with LDL cholesterol levels >130 mg/dl are candidates for active diet therapy. Those whose LDL cholesterol levels are 160 to 190 mg/dl after 3 to 6 months of diet therapy are candidates for drug therapy. A high-density lipoprotein (HDL) level <35 mg/dl is considered a risk factor and may influence the level of LDL at which drug therapy is initiated. Some observers have expressed concern that these guidelines overemphasize LDL cholesterol at the expense of total cholesterol, HDL cholesterol and triglyceride levels. Nevertheless, the guidelines have been broadly accepted and currently serve as the basis for a widespread public-health education program.